Sara Shalin
Concepts (429)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 33 | 2024 | 488 | 8.950 |
Why?
| Skin Diseases | 7 | 2022 | 112 | 4.150 |
Why?
| Melanoma | 16 | 2024 | 285 | 4.010 |
Why?
| Dermatology | 9 | 2024 | 49 | 3.430 |
Why?
| Skin | 12 | 2024 | 409 | 3.260 |
Why?
| Sebaceous Gland Neoplasms | 5 | 2022 | 16 | 1.870 |
Why?
| Carcinoma, Basal Cell | 5 | 2018 | 37 | 1.820 |
Why?
| Immunohistochemistry | 17 | 2021 | 973 | 1.810 |
Why?
| Staining and Labeling | 3 | 2021 | 97 | 1.660 |
Why?
| Adenocarcinoma, Sebaceous | 3 | 2022 | 7 | 1.620 |
Why?
| Biopsy | 18 | 2024 | 584 | 1.620 |
Why?
| Nevus, Blue | 2 | 2021 | 12 | 1.420 |
Why?
| Melanocytes | 3 | 2021 | 37 | 1.410 |
Why?
| Humans | 83 | 2024 | 49974 | 1.370 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 78 | 1.310 |
Why?
| Dermatitis | 2 | 2022 | 36 | 1.290 |
Why?
| Erythema Multiforme | 2 | 2020 | 11 | 1.230 |
Why?
| Female | 46 | 2024 | 26472 | 1.230 |
Why?
| Aged, 80 and over | 18 | 2024 | 3129 | 1.110 |
Why?
| Vulvar Neoplasms | 3 | 2022 | 52 | 1.100 |
Why?
| Middle Aged | 31 | 2024 | 12069 | 1.070 |
Why?
| Nevus, Pigmented | 2 | 2016 | 35 | 1.040 |
Why?
| Alopecia | 2 | 2024 | 39 | 1.040 |
Why?
| Herpes Simplex | 2 | 2022 | 21 | 1.020 |
Why?
| Sebaceous Glands | 2 | 2024 | 14 | 0.980 |
Why?
| Incidental Findings | 1 | 2024 | 39 | 0.960 |
Why?
| Dermatitis, Seborrheic | 1 | 2024 | 4 | 0.950 |
Why?
| Sweat Gland Neoplasms | 3 | 2024 | 22 | 0.950 |
Why?
| Neoplasm Staging | 2 | 2024 | 740 | 0.950 |
Why?
| Diagnosis, Differential | 13 | 2024 | 1037 | 0.950 |
Why?
| Atrophy | 1 | 2024 | 38 | 0.940 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2024 | 116 | 0.910 |
Why?
| Aged | 26 | 2024 | 9310 | 0.900 |
Why?
| Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 15 | 0.900 |
Why?
| Papillomavirus Infections | 2 | 2022 | 155 | 0.890 |
Why?
| Hyperoxaluria | 1 | 2022 | 5 | 0.870 |
Why?
| Hyperoxaluria, Primary | 1 | 2022 | 4 | 0.860 |
Why?
| Urolithiasis | 1 | 2022 | 5 | 0.860 |
Why?
| Graft vs Host Disease | 2 | 2020 | 75 | 0.860 |
Why?
| Adenoma | 2 | 2017 | 110 | 0.850 |
Why?
| Pathology | 2 | 2020 | 33 | 0.850 |
Why?
| Epidermal Cyst | 1 | 2022 | 12 | 0.830 |
Why?
| Adult | 23 | 2024 | 13236 | 0.830 |
Why?
| Granuloma | 2 | 2020 | 43 | 0.830 |
Why?
| Carcinoma in Situ | 1 | 2022 | 73 | 0.810 |
Why?
| Protein Kinases | 2 | 2016 | 71 | 0.810 |
Why?
| Muscle, Smooth | 1 | 2021 | 63 | 0.790 |
Why?
| Fungi | 1 | 2021 | 44 | 0.770 |
Why?
| Elastic Tissue | 2 | 2020 | 10 | 0.770 |
Why?
| Artifacts | 1 | 2021 | 53 | 0.760 |
Why?
| Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.760 |
Why?
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2020 | 2 | 0.750 |
Why?
| Foreign Bodies | 1 | 2021 | 65 | 0.750 |
Why?
| Histiocytoma, Benign Fibrous | 1 | 2020 | 14 | 0.750 |
Why?
| Methenamine | 1 | 2020 | 1 | 0.740 |
Why?
| Periodic Acid-Schiff Reaction | 1 | 2020 | 2 | 0.740 |
Why?
| Lichenoid Eruptions | 1 | 2020 | 3 | 0.740 |
Why?
| Oncogene Proteins, Fusion | 2 | 2020 | 58 | 0.740 |
Why?
| Vulvar Diseases | 1 | 2020 | 7 | 0.740 |
Why?
| Kidney Failure, Chronic | 1 | 2022 | 198 | 0.740 |
Why?
| Genitalia | 1 | 2020 | 11 | 0.730 |
Why?
| Uterine Cervical Dysplasia | 1 | 2020 | 49 | 0.730 |
Why?
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 7 | 0.720 |
Why?
| Lymphatic Metastasis | 2 | 2020 | 224 | 0.720 |
Why?
| Syphilis | 1 | 2020 | 27 | 0.720 |
Why?
| Gynecology | 1 | 2020 | 49 | 0.710 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 70 | 0.700 |
Why?
| Male | 31 | 2024 | 25241 | 0.700 |
Why?
| Pseudoxanthoma Elasticum | 1 | 2019 | 4 | 0.690 |
Why?
| Pathology, Surgical | 1 | 2019 | 18 | 0.670 |
Why?
| Fibroma | 2 | 2020 | 39 | 0.650 |
Why?
| Pathology, Clinical | 4 | 2021 | 24 | 0.650 |
Why?
| Telangiectasis | 1 | 2018 | 3 | 0.630 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.630 |
Why?
| Carcinoma, Squamous Cell | 2 | 2024 | 318 | 0.620 |
Why?
| Carcinoma, Large Cell | 1 | 2017 | 15 | 0.610 |
Why?
| Neoplasms, Multiple Primary | 1 | 2018 | 43 | 0.600 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2017 | 24 | 0.600 |
Why?
| Laryngeal Neoplasms | 1 | 2017 | 42 | 0.600 |
Why?
| Hidrocystoma | 1 | 2017 | 5 | 0.600 |
Why?
| Apocrine Glands | 1 | 2017 | 7 | 0.590 |
Why?
| Calcium Oxalate | 1 | 2017 | 8 | 0.590 |
Why?
| Inflammation | 2 | 2020 | 604 | 0.580 |
Why?
| Young Adult | 10 | 2024 | 3958 | 0.570 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2020 | 202 | 0.550 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 55 | 0.530 |
Why?
| Transcription Factors | 2 | 2021 | 561 | 0.520 |
Why?
| Carcinoma, Merkel Cell | 2 | 2022 | 41 | 0.520 |
Why?
| Brain Neoplasms | 2 | 2020 | 287 | 0.520 |
Why?
| Sarcoptes scabiei | 1 | 2015 | 2 | 0.510 |
Why?
| Scabies | 1 | 2015 | 4 | 0.510 |
Why?
| Genital Diseases, Male | 1 | 2015 | 17 | 0.500 |
Why?
| Lymphangioma | 1 | 2014 | 9 | 0.500 |
Why?
| Histiocytosis, Sinus | 1 | 2015 | 14 | 0.500 |
Why?
| Scrotum | 1 | 2015 | 30 | 0.500 |
Why?
| Arm | 1 | 2014 | 47 | 0.470 |
Why?
| Acanthoma | 1 | 2013 | 2 | 0.460 |
Why?
| Fibroadenoma | 1 | 2013 | 7 | 0.460 |
Why?
| Eccrine Glands | 1 | 2013 | 11 | 0.460 |
Why?
| Nuclear Proteins | 1 | 2014 | 242 | 0.430 |
Why?
| Leuprolide | 1 | 2012 | 2 | 0.430 |
Why?
| Mucinosis, Follicular | 1 | 2012 | 3 | 0.430 |
Why?
| Drug Eruptions | 1 | 2012 | 13 | 0.420 |
Why?
| Endometriosis | 1 | 2012 | 14 | 0.420 |
Why?
| Cicatrix | 1 | 2012 | 40 | 0.420 |
Why?
| Mycosis Fungoides | 1 | 2012 | 27 | 0.410 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2012 | 34 | 0.410 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2012 | 47 | 0.410 |
Why?
| Thrombosis | 1 | 2015 | 248 | 0.400 |
Why?
| Social Media | 3 | 2018 | 97 | 0.390 |
Why?
| Dermis | 2 | 2021 | 18 | 0.390 |
Why?
| Histones | 3 | 2020 | 312 | 0.380 |
Why?
| Cesarean Section | 1 | 2012 | 187 | 0.370 |
Why?
| Vulva | 2 | 2020 | 17 | 0.370 |
Why?
| Vasculitis | 2 | 2024 | 29 | 0.370 |
Why?
| Mucous Membrane | 2 | 2020 | 28 | 0.360 |
Why?
| Muir-Torre Syndrome | 1 | 2010 | 1 | 0.360 |
Why?
| Hippocampus | 3 | 2006 | 228 | 0.340 |
Why?
| Gene Rearrangement | 2 | 2021 | 74 | 0.340 |
Why?
| Adolescent | 7 | 2022 | 6356 | 0.330 |
Why?
| Epithelioid Cells | 2 | 2020 | 12 | 0.310 |
Why?
| Mutation | 4 | 2024 | 1294 | 0.310 |
Why?
| Up-Regulation | 3 | 2020 | 452 | 0.300 |
Why?
| Dermatomycoses | 2 | 2016 | 19 | 0.280 |
Why?
| Leukemia, Myeloid, Acute | 3 | 2016 | 185 | 0.280 |
Why?
| Factor XIIIa | 2 | 2016 | 10 | 0.280 |
Why?
| Mutation, Missense | 3 | 2020 | 105 | 0.270 |
Why?
| Neuronal Plasticity | 1 | 2006 | 58 | 0.270 |
Why?
| MAP Kinase Signaling System | 1 | 2006 | 119 | 0.260 |
Why?
| Memory | 1 | 2006 | 116 | 0.260 |
Why?
| Antifungal Agents | 3 | 2016 | 339 | 0.260 |
Why?
| Memory Disorders | 1 | 2006 | 54 | 0.260 |
Why?
| Postoperative Complications | 1 | 2012 | 984 | 0.260 |
Why?
| Signal Transduction | 2 | 2016 | 1618 | 0.250 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2024 | 3 | 0.250 |
Why?
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2024 | 4 | 0.250 |
Why?
| Skin Diseases, Vascular | 1 | 2024 | 8 | 0.250 |
Why?
| SOXE Transcription Factors | 2 | 2021 | 4 | 0.240 |
Why?
| Neurons | 2 | 2006 | 460 | 0.240 |
Why?
| MART-1 Antigen | 2 | 2021 | 12 | 0.240 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 565 | 0.240 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 51 | 0.230 |
Why?
| Sensitivity and Specificity | 2 | 2024 | 861 | 0.230 |
Why?
| Chickenpox | 1 | 2024 | 18 | 0.230 |
Why?
| Nevus | 1 | 2024 | 17 | 0.230 |
Why?
| Lymphoma | 1 | 2024 | 66 | 0.230 |
Why?
| Fear | 1 | 2004 | 82 | 0.220 |
Why?
| Carcinoma | 1 | 2024 | 138 | 0.220 |
Why?
| Disease Outbreaks | 1 | 2024 | 125 | 0.220 |
Why?
| Oxalates | 1 | 2022 | 12 | 0.220 |
Why?
| Angioedema | 1 | 2022 | 9 | 0.210 |
Why?
| Demography | 1 | 2022 | 93 | 0.210 |
Why?
| Sarcoidosis | 1 | 2022 | 44 | 0.200 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 8 | 0.200 |
Why?
| Foot | 1 | 2022 | 42 | 0.200 |
Why?
| Prednisone | 1 | 2022 | 99 | 0.200 |
Why?
| Plant Structures | 1 | 2021 | 5 | 0.200 |
Why?
| Cotton Fiber | 1 | 2021 | 6 | 0.200 |
Why?
| Paper | 1 | 2021 | 15 | 0.200 |
Why?
| Herpesvirus 2, Human | 1 | 2021 | 5 | 0.200 |
Why?
| Lymphokines | 1 | 2021 | 20 | 0.200 |
Why?
| Herpesvirus 1, Human | 1 | 2021 | 15 | 0.200 |
Why?
| Platelet-Derived Growth Factor | 1 | 2021 | 23 | 0.200 |
Why?
| Histocytochemistry | 1 | 2021 | 44 | 0.200 |
Why?
| Dermatofibrosarcoma | 1 | 2021 | 8 | 0.200 |
Why?
| Herpesvirus 3, Human | 1 | 2021 | 29 | 0.200 |
Why?
| Hyperplasia | 1 | 2021 | 96 | 0.200 |
Why?
| Sutures | 1 | 2021 | 40 | 0.200 |
Why?
| Coloring Agents | 1 | 2021 | 69 | 0.200 |
Why?
| Stromal Cells | 1 | 2021 | 72 | 0.190 |
Why?
| Animals | 10 | 2021 | 13187 | 0.190 |
Why?
| Cadherins | 2 | 2019 | 68 | 0.190 |
Why?
| Retrospective Studies | 4 | 2024 | 6108 | 0.190 |
Why?
| Protein Processing, Post-Translational | 2 | 2020 | 171 | 0.190 |
Why?
| Lost to Follow-Up | 1 | 2020 | 10 | 0.190 |
Why?
| Chromones | 1 | 2021 | 21 | 0.190 |
Why?
| Oncogene Fusion | 1 | 2020 | 4 | 0.190 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 828 | 0.190 |
Why?
| Research Report | 1 | 2020 | 16 | 0.190 |
Why?
| Leprosy, Multibacillary | 1 | 2020 | 5 | 0.190 |
Why?
| Armadillos | 1 | 2020 | 6 | 0.190 |
Why?
| Skin Transplantation | 1 | 2021 | 43 | 0.190 |
Why?
| DNA-Activated Protein Kinase | 1 | 2021 | 26 | 0.180 |
Why?
| S100 Proteins | 2 | 2021 | 34 | 0.180 |
Why?
| Morpholines | 1 | 2021 | 71 | 0.180 |
Why?
| Histiocytes | 1 | 2020 | 10 | 0.180 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2021 | 92 | 0.180 |
Why?
| Neoplasms, Fibrous Tissue | 1 | 2020 | 2 | 0.180 |
Why?
| Phagocytosis | 1 | 2020 | 48 | 0.180 |
Why?
| Graft Survival | 1 | 2021 | 150 | 0.180 |
Why?
| Germ Cells | 1 | 2020 | 12 | 0.180 |
Why?
| Papillomaviridae | 1 | 2020 | 102 | 0.180 |
Why?
| Single-Cell Analysis | 1 | 2020 | 57 | 0.180 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 78 | 0.180 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2020 | 57 | 0.180 |
Why?
| Li-Fraumeni Syndrome | 1 | 2020 | 13 | 0.180 |
Why?
| Immunotherapy | 2 | 2019 | 238 | 0.180 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2020 | 88 | 0.180 |
Why?
| Graft Rejection | 1 | 2021 | 161 | 0.180 |
Why?
| Adenocarcinoma | 1 | 2024 | 396 | 0.170 |
Why?
| Consensus | 1 | 2020 | 148 | 0.170 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 79 | 0.170 |
Why?
| Elastin | 1 | 2019 | 23 | 0.170 |
Why?
| Integrin alpha Chains | 1 | 2019 | 11 | 0.170 |
Why?
| Intracranial Arteriovenous Malformations | 1 | 2019 | 29 | 0.170 |
Why?
| Disease Progression | 3 | 2020 | 825 | 0.160 |
Why?
| Cell Cycle Checkpoints | 1 | 2019 | 32 | 0.160 |
Why?
| Child | 4 | 2022 | 6847 | 0.160 |
Why?
| Melanoma, Experimental | 1 | 2019 | 45 | 0.160 |
Why?
| Arteriovenous Malformations | 1 | 2019 | 67 | 0.160 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 427 | 0.150 |
Why?
| Acute Disease | 1 | 2019 | 366 | 0.150 |
Why?
| Collagen | 1 | 2019 | 206 | 0.150 |
Why?
| Cricoid Cartilage | 1 | 2017 | 11 | 0.150 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 36 | 0.150 |
Why?
| Dilatation | 1 | 2017 | 26 | 0.150 |
Why?
| Antigens, CD | 1 | 2019 | 219 | 0.150 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2018 | 86 | 0.150 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 449 | 0.150 |
Why?
| Tumor Burden | 1 | 2017 | 132 | 0.150 |
Why?
| Connective Tissue Diseases | 1 | 2017 | 16 | 0.150 |
Why?
| Tumor Escape | 1 | 2017 | 16 | 0.150 |
Why?
| Parvoviridae Infections | 1 | 2017 | 20 | 0.150 |
Why?
| Immunologic Surveillance | 1 | 2017 | 10 | 0.150 |
Why?
| Parvovirus B19, Human | 1 | 2017 | 17 | 0.150 |
Why?
| CTLA-4 Antigen | 1 | 2017 | 25 | 0.140 |
Why?
| Rhizopus | 1 | 2016 | 4 | 0.140 |
Why?
| Histone Code | 1 | 2017 | 32 | 0.140 |
Why?
| Trachea | 1 | 2017 | 52 | 0.140 |
Why?
| Sarcoma | 1 | 2018 | 67 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2017 | 38 | 0.140 |
Why?
| RNA, Fungal | 1 | 2016 | 21 | 0.140 |
Why?
| Mucormycosis | 1 | 2016 | 29 | 0.140 |
Why?
| Connexins | 1 | 2016 | 25 | 0.140 |
Why?
| Splenomegaly | 1 | 2016 | 10 | 0.140 |
Why?
| Ascomycota | 1 | 2016 | 9 | 0.140 |
Why?
| Angiomyoma | 1 | 2016 | 5 | 0.140 |
Why?
| Infant | 2 | 2015 | 3567 | 0.140 |
Why?
| Apoptosis | 3 | 2019 | 1101 | 0.140 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2016 | 74 | 0.140 |
Why?
| Osteosarcoma | 1 | 2016 | 47 | 0.140 |
Why?
| Mice | 6 | 2021 | 5739 | 0.140 |
Why?
| Recurrence | 2 | 2015 | 652 | 0.130 |
Why?
| Human Growth Hormone | 1 | 2016 | 50 | 0.130 |
Why?
| Candidiasis | 1 | 2016 | 114 | 0.130 |
Why?
| Education, Medical, Continuing | 1 | 2016 | 68 | 0.130 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 177 | 0.130 |
Why?
| Lung Neoplasms | 2 | 2019 | 606 | 0.130 |
Why?
| Dendritic Cells | 1 | 2016 | 133 | 0.130 |
Why?
| Adipocytes | 1 | 2016 | 121 | 0.130 |
Why?
| Avoidance Learning | 2 | 2006 | 17 | 0.130 |
Why?
| Hamartoma Syndrome, Multiple | 1 | 2015 | 15 | 0.130 |
Why?
| Fibrin | 1 | 2015 | 10 | 0.130 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 16 | 0.130 |
Why?
| Facial Neoplasms | 1 | 2015 | 22 | 0.130 |
Why?
| WT1 Proteins | 1 | 2014 | 4 | 0.130 |
Why?
| Lysine | 1 | 2015 | 89 | 0.130 |
Why?
| Pigmentation Disorders | 1 | 2014 | 5 | 0.130 |
Why?
| Carcinosarcoma | 1 | 2015 | 18 | 0.130 |
Why?
| Osteomyelitis | 1 | 2016 | 126 | 0.120 |
Why?
| Purpura | 1 | 2014 | 7 | 0.120 |
Why?
| Keratin-20 | 1 | 2014 | 7 | 0.120 |
Why?
| Hemangiosarcoma | 1 | 2014 | 16 | 0.120 |
Why?
| Drug Resistance, Neoplasm | 1 | 2017 | 308 | 0.120 |
Why?
| Fellowships and Scholarships | 1 | 2016 | 111 | 0.120 |
Why?
| United States | 2 | 2022 | 4860 | 0.120 |
Why?
| Herpes Zoster | 1 | 2014 | 14 | 0.120 |
Why?
| Eosinophils | 1 | 2015 | 39 | 0.120 |
Why?
| Patient Education as Topic | 1 | 2018 | 302 | 0.120 |
Why?
| Loss of Heterozygosity | 1 | 2015 | 77 | 0.120 |
Why?
| Churg-Strauss Syndrome | 1 | 2014 | 3 | 0.120 |
Why?
| Prospective Studies | 1 | 2020 | 2364 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 128 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 110 | 0.120 |
Why?
| Antigens, CD34 | 1 | 2014 | 66 | 0.120 |
Why?
| Mass Spectrometry | 1 | 2015 | 306 | 0.120 |
Why?
| Lymphocytes | 1 | 2015 | 152 | 0.120 |
Why?
| Exanthema | 1 | 2014 | 32 | 0.120 |
Why?
| Neutrophils | 1 | 2015 | 145 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2016 | 322 | 0.120 |
Why?
| Eosinophilia | 1 | 2014 | 37 | 0.110 |
Why?
| Sarcoma, Kaposi | 1 | 2014 | 72 | 0.110 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 240 | 0.110 |
Why?
| Head and Neck Neoplasms | 1 | 2016 | 268 | 0.110 |
Why?
| Chromosome Aberrations | 1 | 2015 | 297 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 459 | 0.110 |
Why?
| Kaplan-Meier Estimate | 3 | 2020 | 466 | 0.110 |
Why?
| Prognosis | 4 | 2019 | 1942 | 0.110 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2013 | 114 | 0.100 |
Why?
| DNA Mismatch Repair | 1 | 2012 | 17 | 0.100 |
Why?
| Treatment Outcome | 5 | 2021 | 5141 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2014 | 903 | 0.100 |
Why?
| Cell Differentiation | 1 | 2014 | 651 | 0.100 |
Why?
| Multiple Myeloma | 2 | 2016 | 2929 | 0.100 |
Why?
| Asthma | 1 | 2014 | 281 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 595 | 0.080 |
Why?
| Fatal Outcome | 2 | 2022 | 195 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 116 | 0.070 |
Why?
| Phorbol Esters | 1 | 2006 | 3 | 0.070 |
Why?
| Association Learning | 1 | 2006 | 11 | 0.070 |
Why?
| Theta Rhythm | 1 | 2006 | 10 | 0.070 |
Why?
| Amphotericin B | 2 | 2016 | 110 | 0.070 |
Why?
| Child, Preschool | 1 | 2015 | 3871 | 0.070 |
Why?
| Maze Learning | 1 | 2006 | 35 | 0.070 |
Why?
| Mice, Mutant Strains | 1 | 2006 | 71 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 56 | 0.070 |
Why?
| Adrenergic beta-Agonists | 1 | 2006 | 39 | 0.070 |
Why?
| Protein Kinase C | 1 | 2006 | 71 | 0.070 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 83 | 0.070 |
Why?
| Immunocompromised Host | 2 | 2016 | 119 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2016 | 231 | 0.060 |
Why?
| Cell Proliferation | 2 | 2019 | 1007 | 0.060 |
Why?
| T-Lymphocytes | 2 | 2017 | 338 | 0.060 |
Why?
| Nerve Growth Factor | 1 | 2004 | 12 | 0.060 |
Why?
| Superior Cervical Ganglion | 1 | 2004 | 7 | 0.060 |
Why?
| Disease Notification | 1 | 2024 | 10 | 0.060 |
Why?
| Sensory Thresholds | 1 | 2004 | 17 | 0.060 |
Why?
| Time Factors | 2 | 2016 | 2903 | 0.060 |
Why?
| Blotting, Southern | 1 | 2004 | 42 | 0.060 |
Why?
| Exploratory Behavior | 1 | 2004 | 23 | 0.060 |
Why?
| Intellectual Disability | 1 | 2006 | 125 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 50 | 0.060 |
Why?
| Luminescent Proteins | 1 | 2004 | 53 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2004 | 90 | 0.060 |
Why?
| Shock | 1 | 2004 | 35 | 0.060 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 66 | 0.060 |
Why?
| Physician's Role | 1 | 2024 | 48 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 155 | 0.060 |
Why?
| Brain | 2 | 2019 | 1328 | 0.060 |
Why?
| Psychomotor Performance | 1 | 2004 | 130 | 0.060 |
Why?
| Animals, Newborn | 1 | 2004 | 367 | 0.050 |
Why?
| Behavior, Animal | 1 | 2004 | 181 | 0.050 |
Why?
| Motor Activity | 1 | 2004 | 229 | 0.050 |
Why?
| Eyelids | 1 | 2022 | 29 | 0.050 |
Why?
| Blotting, Western | 1 | 2004 | 601 | 0.050 |
Why?
| Mice, Transgenic | 1 | 2004 | 555 | 0.050 |
Why?
| Desmin | 1 | 2022 | 6 | 0.050 |
Why?
| Edema | 1 | 2022 | 67 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 2182 | 0.050 |
Why?
| Gene Expression | 1 | 2004 | 609 | 0.050 |
Why?
| gp100 Melanoma Antigen | 1 | 2021 | 9 | 0.050 |
Why?
| Microphthalmia-Associated Transcription Factor | 1 | 2021 | 4 | 0.050 |
Why?
| DNA, Viral | 1 | 2021 | 133 | 0.050 |
Why?
| Mycobacterium leprae | 1 | 2020 | 8 | 0.050 |
Why?
| Soil Microbiology | 1 | 2020 | 18 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2021 | 259 | 0.050 |
Why?
| Societies, Medical | 1 | 2021 | 175 | 0.050 |
Why?
| RNA, Messenger | 1 | 2004 | 1105 | 0.050 |
Why?
| Retinoblastoma Protein | 1 | 2020 | 19 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 1376 | 0.050 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 16 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 304 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2021 | 247 | 0.040 |
Why?
| Cells, Cultured | 1 | 2004 | 1573 | 0.040 |
Why?
| Ulcer | 1 | 2020 | 22 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 2020 | 56 | 0.040 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 134 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 173 | 0.040 |
Why?
| Rats, Sprague-Dawley | 1 | 2004 | 1597 | 0.040 |
Why?
| Germ-Line Mutation | 1 | 2020 | 61 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 55 | 0.040 |
Why?
| Malpractice | 1 | 2019 | 15 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 280 | 0.040 |
Why?
| Microcirculation | 1 | 2019 | 70 | 0.040 |
Why?
| Diagnostic Errors | 1 | 2019 | 63 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2020 | 402 | 0.040 |
Why?
| Fibrosis | 1 | 2019 | 179 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2020 | 577 | 0.040 |
Why?
| Survival Analysis | 1 | 2020 | 653 | 0.040 |
Why?
| Flow Cytometry | 1 | 2021 | 476 | 0.040 |
Why?
| Transcriptome | 1 | 2020 | 315 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 465 | 0.040 |
Why?
| Rare Diseases | 1 | 2018 | 44 | 0.040 |
Why?
| Larynx | 1 | 2017 | 30 | 0.040 |
Why?
| Rats | 1 | 2004 | 3305 | 0.040 |
Why?
| Cadaver | 1 | 2017 | 97 | 0.040 |
Why?
| Pressure | 1 | 2017 | 105 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2019 | 212 | 0.040 |
Why?
| Forkhead Transcription Factors | 1 | 2018 | 112 | 0.040 |
Why?
| Immunomodulation | 1 | 2017 | 37 | 0.040 |
Why?
| Forearm | 1 | 2016 | 31 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2017 | 47 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 510 | 0.040 |
Why?
| Debridement | 1 | 2016 | 46 | 0.040 |
Why?
| Pilot Projects | 1 | 2019 | 699 | 0.040 |
Why?
| Blood Cell Count | 1 | 2016 | 37 | 0.040 |
Why?
| Toes | 1 | 2016 | 15 | 0.040 |
Why?
| Induction Chemotherapy | 1 | 2016 | 60 | 0.030 |
Why?
| Family | 1 | 2018 | 170 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2017 | 454 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2017 | 172 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2016 | 61 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2016 | 119 | 0.030 |
Why?
| Treatment Refusal | 1 | 2016 | 37 | 0.030 |
Why?
| Abscess | 1 | 2016 | 41 | 0.030 |
Why?
| Triazoles | 1 | 2016 | 108 | 0.030 |
Why?
| Cell Movement | 1 | 2017 | 247 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 183 | 0.030 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 44 | 0.030 |
Why?
| Epigenomics | 1 | 2016 | 67 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2021 | 1455 | 0.030 |
Why?
| Methylation | 1 | 2015 | 122 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 453 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 1816 | 0.030 |
Why?
| Proteome | 1 | 2017 | 173 | 0.030 |
Why?
| Pedigree | 1 | 2015 | 125 | 0.030 |
Why?
| Comparative Genomic Hybridization | 1 | 2015 | 47 | 0.030 |
Why?
| Scalp | 1 | 2015 | 40 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2016 | 466 | 0.030 |
Why?
| Hyperlipidemias | 1 | 2014 | 49 | 0.030 |
Why?
| Arkansas | 1 | 2020 | 1977 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2015 | 175 | 0.030 |
Why?
| Bone Marrow | 1 | 2016 | 362 | 0.030 |
Why?
| Respiratory Function Tests | 1 | 2014 | 90 | 0.030 |
Why?
| Reoperation | 1 | 2016 | 454 | 0.030 |
Why?
| Lipodystrophy | 1 | 2013 | 9 | 0.030 |
Why?
| Heterozygote | 1 | 2013 | 81 | 0.030 |
Why?
| Incidence | 1 | 2016 | 1003 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2013 | 70 | 0.030 |
Why?
| Syndrome | 1 | 2013 | 237 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2016 | 614 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 374 | 0.030 |
Why?
| Risk Assessment | 1 | 2016 | 1259 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1403 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2014 | 945 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 1537 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1159 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2016 | 1171 | 0.020 |
Why?
|
|
Shalin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|